IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
NCT ID: NCT05014698
Last Updated: 2026-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
34 participants
INTERVENTIONAL
2022-02-23
2026-01-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnosing Thyroid Cancer Using a Blood Test
NCT01586520
Hereditary Risk Factors for Thyroid Cancer
NCT02747888
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)
NCT05541380
Prognostic Markers for a Better Follow-up in Head and Neck Cancer.
NCT06094985
Molecular and Genomic Profiling of Head and Neck Tumors
NCT00200486
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Furthermore, the discovery of new genes would be a major medical advance that could contribute to the identification of new therapeutic targets.
This research will be conducted at the University Hospital of Nantes and the Hospital of Vendée and 95 people should participate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
WGS
at inclusion visit :
\- Blood collection for whole Genome sequencing will be performed
At final visit :
the results of the WGS will be delivered to patients
WGS
Whole Genome sequencing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WGS
Whole Genome sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Minor or adult subject
* Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent
* Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes
* Patient affiliated to a valid social security plan
Relative subjects
* Adult subjects
* Subject agreeing to sign the study consent and the biocollection consent
* Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes
* Patient affiliated to a social security plan
Exclusion Criteria
* Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1
* Subjects under guardianship, curatorship or safeguard of justice or not socially insured
* Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)
8 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vendée Hospital
La Roche-sur-Yon, , France
Nantes University Hospital
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC19_0414
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.